A groundbreaking three-year campaign led by Gavi, the Vaccine Alliance, has successfully prevented an estimated 1.4 million cervical cancer deaths in low-income countries. The initiative, which focused on delivering human papillomavirus (HPV) vaccines, has protected 86 million girls against the leading cause of cervical cancer. Gavi announced this milestone on World Cervical Cancer Elimination Day, highlighting the disproportionate impact of HPV-related cancers in low-income regions, which accounted for 90% of the 350,000 cervical cancer deaths recorded in 2022. These areas often lack access to screening and treatment services, exacerbating the crisis. Gavi’s CEO, Sania Nishtar, praised the ‘incredible commitment’ of participating countries and organizations in achieving this life-saving goal. The vaccine coverage rate in Africa surged from 4% in 2014 to 44% by the end of 2024, surpassing Europe’s 38% rate. Gavi leveraged economies of scale to reduce vaccine costs, making doses available for as low as $2.90 to $5.18 in supported countries, compared to over $100 elsewhere. The World Health Organization’s 2022 endorsement of a single-dose HPV vaccination schedule further doubled the reach of existing vaccine stocks. Despite these advances, cervical cancer remains a critical threat, claiming a woman’s life every two minutes. Gavi’s efforts underscore the importance of global collaboration in combating this preventable disease.